Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Director | June 15, 2022 | June 17, 2022 |
| Bausch Health Companies Inc.BHC · Entity 4363 | Director | May 16, 2025 | May 20, 2025 |
| INTERNATIONAL FLAVORS & FRAGRANCES INCIFF · Entity 3234 | Director | May 01, 2026 | May 04, 2026 |
| Sana Biotechnology, Inc.SANA · Entity 4870 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date June 15, 2022 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,099 |
Reported balance
After 2022-06-15 transaction · row 1
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 1,370 · Balance 15,099 |
Bausch Health Companies Inc.
Report date May 16, 2025 · Filed May 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 155,616 |
Reported balance
After 2025-05-16 transaction · row 1
1 source rowRow 1 · 2025-05-16 · Grant · Acquired 54,347 · Balance 155,616 F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer.
INTERNATIONAL FLAVORS & FRAGRANCES INC
Report date May 01, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,712 |
Reported balance
After 2026-05-01 transaction · row 1
1 source rowRow 1 · 2026-05-01 · Exercise / conversion · Acquired 1,712 · Balance 1,712 F1: Represent RSUs granted under the Non-Employee Director Compensation Program. F2: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-01 · Exercise / conversion · Disposed 1,712 · Balance 0 F2: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. F1: Represent RSUs granted under the Non-Employee Director Compensation Program. F3: On November 3, 2025, the reporting person was granted 1,712 restricted stock units, all of which vested on May 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represent RSUs granted under the Non-Employee Director Compensation Program.
F2: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis.
F3: On November 3, 2025, the reporting person was granted 1,712 restricted stock units, all of which vested on May 1, 2026.
Sana Biotechnology, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-03 | Direct | 90,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 90,000 · Balance 90,000 F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 20:36 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001376247-26-000002 · primarydocument.xml · derivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| May 01, 2026 Filed May 4, 2026 21:09 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | Exercise / conversionRestricted Stock Units · Derivative | 1,712 | $70.81 | $121,226.72 |
DisclosureSEC source: 0001225208-26-004883 · doc4.xml · derivative · entry 2 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,712 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. F1 · shares: Represent RSUs granted under the Non-Employee Director Compensation Program. F3 · derivative.exercise_date: On November 3, 2025, the reporting person was granted 1,712 restricted stock units, all of which vested on May 1, 2026. F3 · derivative.expiration_date: On November 3, 2025, the reporting person was granted 1,712 restricted stock units, all of which vested on May 1, 2026. Read SEC document |
| May 01, 2026 Filed May 4, 2026 21:09 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | Exercise / conversionCommon Stock | 1,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-004883 · doc4.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represent RSUs granted under the Non-Employee Director Compensation Program. F2 · price: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. Read SEC document |
| April 29, 2026 Filed Apr 30, 2026 20:29 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantRestricted Stock Units · Derivative | 2,903 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-004738 · doc4.xml · derivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,903 Underlying: Common Stock · 2,903 shares Expires 2027-04-29 F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. F2 · shares: Represent RSUs granted under the Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The RSUs will vest on the one-year anniversary of the grant date. F3 · derivative.expiration_date: The RSUs will vest on the one-year anniversary of the grant date. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 21:21 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantRestricted Stock Units · Derivative | 1,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-008915 · doc4.xml · derivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,712 Underlying: Common Stock · 1,712 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. F2 · derivative.expiration_date: The RSUs will vest on May 1, 2026. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:40 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001562180-25-004644 · primarydocument.xml · derivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:29 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 54,347 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015024 · form4.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,616 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| September 25, 2024 Filed Sep 26, 2024 20:07 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 150,000 | $3.89 | $583,170.00 |
DisclosureSEC source: 0001562180-24-006954 · primarydocument.xml · nonDerivative · entry 2 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,698,121 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 25, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.69 to $4.13, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 24, 2024 Filed Sep 26, 2024 20:07 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 150,000 | $4.08 | $612,570.00 |
DisclosureSEC source: 0001562180-24-006954 · primarydocument.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,848,121 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 25, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.00 to $4.16, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:22 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 54,278 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001562180-24-004845 · primarydocument.xml · derivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,278 Underlying: Common Stock · 54,278 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| June 06, 2024 Filed Jul 15, 2024 20:13 UTC Amendment | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001562180-24-005723 · primarydocument.xml · derivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2034-06-05 F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. Read SEC document |
| May 17, 2024 Filed May 20, 2024 21:53 UTC Amendment | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 35,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016031 · form4a.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,269 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| May 19, 2023 Filed May 19, 2023 20:16 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 29,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016290 · form4.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,909 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:32 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Options (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-23-002394 · primarydocument.xml · derivative · entry 1 Mulligan Richard · CIK 0001376247 · Director · Head of SanaX 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-03-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 2, 2024 and in 36 equal monthly installments thereafter. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 20:35 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 34,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-018200 · form4.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,704 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:03 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017797 · form4.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,099 Read SEC document |
| May 13, 2022 Filed May 17, 2022 22:04 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 2,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-014807 · form4.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,317 F1 · shares: Represents Restricted Share Units ("RSUs"), each representing a contingent right to receive one Common Share, no par value, of Bausch Health Companies Inc., which will vest immediately before the 2022 Annual Meeting of Shareholders. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 14:06 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Options (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001562180-22-002428 · primarydocument.xml · derivative · entry 1 Mulligan Richard · CIK 0001376247 · Director · Head of SanaX 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-03-02 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:30 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-021341 · form4.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,729 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019027 · form4.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,954 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:51 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022420 · form4.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,064 Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:32 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-020962 · form4.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,909 Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 21:55 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-021103 · form4.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,029 F1 · balance_after: On 6/8/16 an RSU was awarded for 1,060 shares. This award was adjusted to 1,084 shares pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.